Imaging In-Depth Focus 2017
Posted: 11 September 2017 | Drug Target Review | No comments yet
This In-Depth Focus explores current uses and future development in mass spectrometry imaging for bringing new drugs to market…
Articles featured in this Imaging In-Depth Focus:
- Mass spectrometry imaging in drug discovery
Richard JA Goodwin (AstraZeneca), Josephine Bunch (National Physical Laboratory) - Visualising the effects of targeted therapies on patient tumours
James O’Connor (University of Manchester)
Also includes:
- Expert view: Bridging the gap in users’ needs
Guillaume Frugier (Molecular Devices)
The digital version of this In-Depth Focus is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Drug Discovery, Mass Spectrometry, X-ray crystallography
Related conditions
Tumours
Related organisations
AstraZeneca, National Physical Laboratory, University of Manchester
Related people
Dr Josephine Bunch, James O'Connor, Richard Goodwin
